June 8, 2026 - 10:49

Genworth Financial continues to lean heavily on its majority stake in Enact Holdings, a mortgage insurance provider that now stands as the company's most valuable asset. With Enact currently valued at roughly $4.7 billion, Genworth's own market capitalization remains surprisingly low in comparison. This disconnect suggests that the broader market has not fully priced in the worth of Genworth's core holding.
Analysts point out that Genworth's stock trades at a significant discount to the implied value of its Enact shares alone. If you strip out the value of the Enact stake, the rest of Genworth's business -- including its legacy life insurance and long-term care operations -- appears to be valued at a fraction of what it might be worth. This creates a compelling opportunity for investors who see the gap narrowing over time.
The company has also made progress in managing its older insurance liabilities, which have long been a drag on its balance sheet. While those legacy risks are not gone, they are better contained than in previous years. As Enact continues to generate steady profits, Genworth is in a stronger position to address its remaining obligations.
For now, the stock remains a buy for those willing to bet that the market will eventually recognize the true value of the Enact holding. The discount is wide, but the driver is clear.
August 10, 2026 - 04:13
Essential Utilities Q2 Earnings Call HighlightsEssential Utilities reported second-quarter earnings of 37 cents per share on a GAAP basis, a slight dip from the 38 cents recorded in the same period last year. The company cited higher regulatory...
August 9, 2026 - 15:48
Tronox Q2 Earnings Call HighlightsTronox reported second-quarter revenue of $868 million, a 19 percent increase compared to the same period last year. The gains came from stronger titanium dioxide and zircon volumes, which helped...
August 8, 2026 - 19:01
Eli Lilly and Company Q2 Earnings Call HighlightsEli Lilly and Company posted a 48 percent jump in revenue for the second quarter of 2026, powered by sustained demand for its blockbuster cardiometabolic treatments MOUNJARO and ZEPBOUND. The...
August 8, 2026 - 04:20
Marblehead heads toward first override accounting amid finance turnoverMarblehead is moving closer to its first-ever override accounting process, but the timing could not be more complicated. The town is losing another key finance official, with Pfifferling departing...